REPUBLIC OF KENYA

MINISTRY OF HEALTH
PHARMACY AND POISONS BOARD

PUBLIC ALERT

FALSIFIED PHESGO (PERTUZUMAB/TRASTUZUMAB) 600MG/600MG IN 10ML, BATCH NUMBER C5290S20

The Pharmacy and Poisons Board ("the Board") is mandated by Cap 244 of the Laws of Kenya to protect and promote public health by regulating the pharmacy profession and ensuring access to quality, safe, and effective health products and technologies ("HPTs").

In furtherance of this mandate, the Board undertakes post-marketing surveillance activities to monitor HPTs circulating in the market and to take appropriate regulatory actions in safeguarding public health.

During the course of these surveillance activities, the Board has identified a falsified batch of **Phesgo (Pertuzumab/Trastuzumab)**, Batch Number **C5290S20**, currently circulating in the Kenyan market. The falsified batch contains discrepancies compared to the genuine Phesgo as follows:

1. Batch Number C5290S20 does not correspond to any authentic Roche batch number.
2. The vial contains a white powder, whereas genuine Phesgo is a ready-to-use, clear to opalescent, colorless to slightly brownish liquid solution intended for subcutaneous administration. Phesgo is never supplied as a powder and does not require reconstitution.

The falsified batch may contain incorrect, insufficient, or harmful ingredients, and its quality, safety, and efficacy cannot be guaranteed. Use of this product poses a serious risk to patient safety and public health

PUBLIC ADVISORY

1. Procurement agencies, distributors, wholesalers and retailers, pharmacists, pharmaceutical technologists, all healthcare professionals and members of the public should **immediately stop the distribution and use of Phesgo (Pertuzumab/Trastuzumab), Batch Number C5290S20** and **report any encounter with this falsified batch** to the Pharmacy and Poisons Board.

2. All stakeholders within the supply chain to procure HPTs exclusively from licensed manufacturers, importers, distributors, and retailers. Procuring from unlicensed sources endangers patients and constitutes a violation of the Pharmacy and Poisons Act, Cap 244 of the Laws of Kenya.

The Board, together with relevant Government investigative agencies, will take firm action against any individual or entity involved in the distribution of this and any other falsified batches of HPTs.

HOW TO REPORT

Any suspected falsified or substandard medicine, should be reported through the following official channels:

- Online portal: https://pv.pharmacyboardkenya.org/users/mpublic
- USSD Code: *271#
- Mobile App: mPvERS (Android & iOS)
- Email: pv@ppb.go.ke | pms@ppb.go.ke
- Telephone: 0795743049

The Pharmacy and Poisons Board remains committed to protecting and safeguarding public health. Your cooperation is essential in ensuring the quality, safety and efficacy of Health Products and Technologies in Kenya.

Dr. Ahmed I. Mohamed
Ag. CHIEF EXECUTIVE OFFICER
25th May 2026

PRODUCT PHOTO